Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 228

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

Open access
de Groot, John F., Lamborn, Kathleen R., Chang, Susan M., Gilbert, Mark R., Cloughesy, Timothy F., Aldape, Kenneth, Yao, Jun, Jackson, Edward F., Lieberman, Frank, Robins, H. Ian, Mehta, Minesh P., Lassman, Andrew B., DeAngelis, Lisa M., Yung, W.K. Alfred, Chen, Alice, Prados, Michael D., Wen, Patrick Y.·2011·Journal of Clinical Oncology

Abstract

Purpose: Antivascular endothelial growth factor (anti-VEGF) therapy is a promising treatment approach for patients with recurrent glioblastoma. This single-arm phase II study evaluated the efficacy of aflibercept (VEGF Trap), a recombinantly produced fusion protein that scavenges both VEGF and placental growth factor in patients with recurrent malignant glioma. Patients and Methods: Forty-two patients with glioblastoma and 16 patients with anaplastic glioma who had received concurrent radiation and temozolomide and adjuvant temozolomide were enrolled at first relapse. Aflibercept 4 mg/kg was administered intravenously on day 1 of every 2-week cycle. Results: The 6-month progression-free survival rate was 7.7% for the glioblastoma cohort and 25% for patients with anaplastic glioma. Overall radiographic response rate was 24% (18% for glioblastoma and 44% for anaplastic glioma). The median progression-free survival was 24 weeks for patients with anaplastic glioma (95% CI, 5 to 31 weeks) and 12 weeks for patients with glioblastoma (95% CI, 8 to 16 weeks). A total of 14 patients (25%) were removed from the study for toxicity, on average less than 2 months from treatment initiation. The main treatment-related National Cancer Institute Common Terminology Criteria grades 3 and 4 adverse events (38 total) included fatigue, hypertension, and lymphopenia. Two grade 4 CNS ischemias and one grade 4 systemic hemorrhage were reported. Aflibercept rapidly decreases permeability on dynamic contrast enhanced magnetic resonance imaging, and molecular analysis of baseline tumor tissue identified tumor-associated markers of response and resistance. Conclusion: Aflibercept monotherapy has moderate toxicity and minimal evidence of single-agent activity in unselected patients with recurrent malignant glioma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.34.1636

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 228

Metadata

Authors
de Groot, J. F., Lamborn, K. R., Chang, S. M., Gilbert, M. R., Cloughesy, T. F., Aldape, K., Yao, J., Jackson, E. F., Lieberman, F., Robins, H. I., Mehta, M. P., Lassman, A. B., DeAngelis, L. M., Yung, W. K. A., Chen, A., Prados, M. D., & Wen, P. Y.
Venue
Journal of Clinical Oncology
Published
2011-07-01
Volume
29
Issue
19
Pages
2689-2695
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2161190434
Cited by
228
References
5
FWCI
14.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. https://app.cochat.ai/papers/10.1200/jco.2010.34.1636
The paper
de Groot, J. F., Lamborn, K. R., Chang, S. M., Gilbert, M. R., Cloughesy, T. F., Aldape, K., Yao, J., Jackson, E. F., Lieberman, F., Robins, H. I., Mehta, M. P., Lassman, A. B., DeAngelis, L. M., Yung, W. K. A., Chen, A., Prados, M. D., & Wen, P. Y. (2011). Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.34.1636

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.